Research graph
References from Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review. Local targets link to admitted publications; unresolved targets remain external evidence.
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
10.1038/s41573-021-00266-6 · 2022 · External reference
Challenges and Future Trends in Atopic Dermatitis.
10.3390/ijms241411380 · 2023 · External reference
The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.
External reference
Atopic dermatitis.
10.1016/s0140-6736(20)31286-1 · 2020 · External reference
Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines
10.1016/j.jaip.2017.08.031 · 2017 · External reference
Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus.
10.2340/actadv.v103.12314 · 2023 · External reference
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
10.1016/j.jid.2016.08.022 · 2017 · External reference
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.
10.2340/00015555-3751 · 2021 · External reference
Update on the Pathogenesis and Therapy of Atopic Dermatitis.
10.1007/s12016-021-08880-3 · 2021 · External reference
Systemic Treatment of Adult Atopic Dermatitis: A Review.
10.1007/s13555-016-0170-1 · 2017 · External reference
Current Perspectives on the Systemic Management of Atopic Dermatitis.
10.2147/jaa.s287638 · 2021 · External reference
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence.
10.1016/j.xjidi.2023.100195 · 2023 · External reference
Updated Review on Treatment of Atopic Dermatitis.
10.18176/jiaci.0906 · 2023 · External reference
The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis.
10.1080/09546634.2021.1942422 · 2022 · External reference
Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
10.1159/000518541 · 2022 · External reference
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis
10.1007/s00228-022-03400-4 · 2022 · External reference
The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis
10.1016/j.jaad.2022.03.039 · 2022 · External reference
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
10.1016/j.jaci.2019.11.025 · 2020 · External reference
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study.
10.1007/s13555-022-00842-7 · 2023 · External reference
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
10.1016/j.jaci.2021.07.036 · 2022 · External reference
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
10.1001/jamadermatol.2022.0029 · 2022 · External reference
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
10.1111/jdv.19232 · 2023 · External reference
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
10.1371/journal.pmed.1000100 · 2009 · External reference
Waiting for JAK inhibitor safety data.
10.1136/rmdopen-2022-002236 · 2022 · External reference
JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
10.3389/fimmu.2022.1068260 · 2022 · External reference
Atopic Dermatitis: Pathophysiology
10.1007/978-3-319-64804-0_3 · 2017 · External reference
JAK inhibitors in the treatment of atopic dermatitis
10.1016/j.jaci.2021.08.009 · 2021 · External reference
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors.
10.3390/jpm13030384 · 2023 · External reference
10.1186/s41927-018-0031-x · 2018 · Admitted local publication
The interferon signaling network and transcription factor C/EBP-beta.
2007 · External reference
Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis
10.1172/jci82887 · 2016 · External reference
The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
10.1016/j.jaci.2015.03.051 · 2015 · External reference
STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch
10.1038/nm.3912 · 2015 · External reference
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study.
2023 · External reference
Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment
10.1111/exd.13514 · 2018 · External reference
Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures
10.1016/j.jaci.2018.02.047 · 2018 · External reference
Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features
10.1016/j.jaci.2018.06.016 · 2018 · External reference
Resolving the etiology of atopic disorders by using genetic analysis of racial ancestry
10.1016/j.jaci.2016.02.045 · 2016 · External reference
Racial differences in atopic dermatitis
10.1016/j.anai.2018.11.015 · 2019 · External reference
Assessment and Monitoring Challenges Among Patients With Moderate-to-Severe Atopic Dermatitis Across Fitzpatrick Skin Types: A Photographic Review and Case Series.
2022 · External reference
